MSFrontier

NA

No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis
Moved to EU CTIS registryPhase 2Relapsing MS2022-002654-95

What was tested

Treatment tested

  • Filgrastim

    Granulocyte colony stimulating factor receptor agonist

  • Carmustine

    DNA inhibitor|Glutathione reductase inhibitor|RNA inhibitor

  • Etoposide

    DNA topoisomerase II inhibitor

  • Cytarabine

    DNA inhibitor|DNA polymerase (alpha/delta/epsilon) inhibitor|RNA inhibitor

  • CICLOFOSFAMIDE MONOIDRATA
  • IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI
  • MELFALAN CLORIDRATO

Compared with

  • Ocrelizumab

    B-lymphocyte antigen CD20 binding agent

  • Ofatumumab

    B-lymphocyte antigen CD20 binding agent

  • Natalizumab

    Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor

  • Alemtuzumab

    CAMPATH-1 antigen inhibitor

What it measured

Main measures

  • The primary outcome is the occurrence of any evidence of multiple sclerosis disease activity (NEDA-3) over 36 months, analyzed as time-to-event.

Other measures (1)

  • 1. The proportion of participants who experience a serious adverse event [Time frame: from day 0 up to 36 months]

    Safety

Papers

    Loading reviews and guidelines…

    Related trials

    • NET-MS

      Phase 2 · Stopped early

      Stopped early

    • StarMS

      Phase 3 · Completed (inferred)

      Result in a paper, not read yet

    • RAM-MS

      Phase 3 · Running, not recruiting

      Still running

    • MOST

      Phase 3 · Stopped early

      Stopped early

    • RAM-MS

      Phase 3 · Moved to EU CTIS registry

    • HiCy

      Phase 2 · Withdrawn

      Stopped early

    History

    1. In scope changed from true to false

    1. Started

      Jan 2023

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error